Fusion proteins bcr abl. Medical search. Frequent questions

Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. (jefferson.edu)
It attaches (fuses) to part of the BCR gene on chromosome 22. (medlineplus.gov)
This chromosome results from the faulty fusion of two genes - Bcr from chromosome 22, and Abl on chromosome 9. (rxwiki.com)
The ABL gene on chromosome 9 breaks off and combines with the BCR gene from chromosome 22. (usahealthsystem.com)
Two principal breaks occur in the (breakpoint cluster region) gene locus on chromosome 22: the (major) M-BCR, between exons 12 and 16, and the (minor) m-BCR, in the first intron of and m-BCR to that of p185(Abelson tyrosin protein kinase 1) gene on chromosome 9 falls within the intron between the exons 1 and 2. (bios-mep.info)
During this translocation, a piece of chromosome 9 containing the oncogene ABL is translocated to chromosome 22 and fused to the BCR gene. (msdmanuals.com)

Genes whose protein products stimulate or enhance the division and viability of cells. (cancerquest.org)
Genes whose protein products can directly or indirectly prevent cell division or lead to cell death. (cancerquest.org)
The abnormal BCR-ABL1 gene is made when two separate genes merge together and become one gene. (medlineplus.gov)
Your genes carry special instructions for making proteins that help your cells do their work. (medlineplus.gov)
See how well your treatment is working (if treatment is helping, the number of cells with BCR-ABL1 genes will decrease. (medlineplus.gov)
The multifunctional regulator nuclear factor erythroid 2-related factor (Nrf2) is considered not only as a cytoprotective factor regulating the expression of genes coding for anti-oxidant, anti-inflammatory and detoxifying proteins, but it is also a powerful modulator of species longevity. (springer.com)
The major characteristics of Nrf2 are to some extent mimicked by Nrf2-dependent genes and their proteins including heme oxygenase-1 (HO-1), which besides removing toxic heme, produces biliverdin, iron ions and carbon monoxide. (springer.com)
Fusion proteins , also known as chimeric proteins , are proteins created through the joining of two or more genes which originally coded for separate proteins. (chemeurope.com)
Chimeric mutant proteins occur natually when a large-scale mutation , typically a chromosomal translocation, creates a novel coding sequence containing parts of the coding sequences from two different genes. (chemeurope.com)
Naturally occurring fusion genes are most commonly created when a chromosomal translocation replaces the terminal exons of one gene with intact exons from a second gene. (chemeurope.com)
Many important cancer-promoting oncogenes are fusion genes produced in this way. (chemeurope.com)
Non-receptor tyrosine kinases encoded by the C-ABL GENES. (jefferson.edu)
His team has characterized more than 25 different translocations and found that the majority result in fusion genes encoding chimeric proteins with an N-terminal region derived from a partner gene fused in frame to the C-terminal region of tyrosine kinase such as ABL, PDGFRα, PDGFRß, JAK2, KIT or FGFR1. (cml-foundation.org)
Expression of bcr-abl mRNA and MMR genes mRNA were detected by RT-PCR in 26 CML patients with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) and 4 CML patients on imatinib treatment. (hku.hk)

Proto-Oncogene Proteins c-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications. (jefferson.edu)
Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles. (jefferson.edu)

Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. (lu.se)
The introduction of imatinib, a selective inhibitor of the ABL tyrosine kinase, has revolutionized the treatment and the outcome of this subset of patients [ 1 ]. (hindawi.com)
Recently "natural" bcr-abl breakpoint-specific cytotoxic T lymphocytes (CTLs) were found in the bone marrow of Ph+ ALL patients treated with imatinib correlating with a better response to this TKI [ 6 ]. (hindawi.com)
T315I mutated BCR-ABL is the main cause of the resistance mediated by imatinib and second generation BCR-ABL inhibitor. (jcancer.org)
Here, we determined the effect of Jiyuan oridonin A (JOA), an ent -kaurene diterpenoid compound, on the differentiation blockade in imatinib-sensitive, particularly, imatinib-resistant CML cells with BCR-ABL-T315I mutation by cell proliferation assay, apoptosis analysis, cell differentiation analysis, cell cycle analysis and colony formation assay. (jcancer.org)
JOA displayed the activity of inhibiting the BCR-ABL and promoted differentiation of not only imatinib -sensitive but also imatinib -resistant cells with BCR-ABL mutation, which could become a potent lead compound to overcome the imatinib -resistant induced by inhibitors of BCR-ABL tyrosine kinase in CML therapy. (jcancer.org)
Therefore, imatinib was a paradigm of targeted therapies, which due to that imatinib inhibits the phosphorylation of BCR-ABL then suppress the activation of BCR-ABL tyrosine kinase [ 6 ]. (jcancer.org)
Targeting BCR/ABL by selective ATP competitors, such as imatinib or nilotinib, is a well validated therapeutic concept, but unable to definitively eradicate the disease. (bios-mep.info)
Bcr-Abl fusion protein has constitutively activated Abl tyrosine kinase activity which is responsible for the uncontrolled proliferation in CML The tyrosine kinase inhibitors (TKIs) such as Imatinib, Dasatinib, and Nilotinib are the current first-line treatments approved by the United States Food and Drug Administration (US FDA) for the treatment of the disease. (eurekaselect.com)
In 26 CML with allo-PBSCT and 4 CML patients on imatinib treatment, expressions of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while expression of bcr-abl mRNA decreased. (hku.hk)
In CML MNC after imatinib treatment and in K562 cells, expression of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while tyrosine phosphorylation of BCR-ABL fusion protein decreased. (hku.hk)

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. (jefferson.edu)
Also new antibody clones against rigorously selected epitopes of proteins involved in chromosomal translocations were developed for detection of most frequent fusion proteins in acute leukemia and chronic myeloid leukemia. (wikipedia.org)
The bcr-abl fusion protein is a well-known example of an oncogenic fusion protein, and is considered to be the primary oncogenic driver of chronic myelogenous leukemia. (chemeurope.com)
Chronic myeloid leukemia (CML) results from BCR-ABL oncogene, which blocks CML cells differentiation and protects these cells from apoptosis. (jcancer.org)
Chronic myeloid leukemia (CML) is a clonal expansion of the progenitor hematopoietic stem cells arising from the existence of the fusion BCR-ABL oncogene, that represents 15%-20% of the newly diagnosed cases of leukemia patients [ 1 - 2 ]. (jcancer.org)
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused due to translocation between chromosome 9 and 22 leading to a chimeric gene product known as Bcr-Abl. (eurekaselect.com)
Stone, M. Translocation of C-Abl oncogene correlates with the presence of a philadelphia chromosome in chronic myelocytic leukaemia. (eurekaselect.com)
Human chronic myelogenous leukemia (CML) is characterized by a translocation between chromosomes 9 and 22 that results in a BCR-ABL fusion gene coding for chimeric proteins. (pasteur.fr)
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by the chromosomal translocation t(9;22) encoding for the Bcr/Abl fusion gene. (wcrj.net)

On the other hand about 30% of patients with Ph+ ALL harbor the M-BCR p210or p210[5,6,7]. (bios-mep.info)

Both technologies have been primarily focused on measurement of protein epitopes, but have been used to measure nucleic acids such as targeted mRNA 11 , 12 . (nature.com)
A blood test, typically performed every three months, measures the level of BCR-ABL mRNA present in the patient's blood. (usahealthsystem.com)
Dr Cross has a long-standing career in the development of genetic tests and is particularly committed to the development and standardisation of molecular monitoring for CML patients worldwide by qRT-PCR for BCR-ABL mRNA. (cml-foundation.org)
Expression of bcr-abl mRNA was detected by RT-PCR and tyrosine phosphorylation of BCR-ABL fusion protein by Western blot. (hku.hk)
CONCLUSION: Expressions of hMSH2, hMSH3 and hMLH1 mRNA were down-regulated by bcr-abl fusion gene. (hku.hk)

Today's medications, called tyrosine kinase inhibitors, target this protein. (rxwiki.com)
For most patients with CML, BCR-ABL tyrosine kinase inhibitors (TKIs) have turned the an inevitably fatal disease into a manageable condition. (jcancer.org)
Cooperativity between ß-agonists and c-Abl inhibitors in regulating airway smooth muscle relaxation. (jefferson.edu)
This review outlines the Bcr-Abl dependent and independent mechanism of TKIs resistance development and the strategies used to overcome drug resistance, such as the development of ATP site and allosteric site inhibitors. (eurekaselect.com)
Kaiso and prognosis As expected for a transcriptional aspect, the Kaiso Inhibitors,Modulators,Libraries protein is often discovered while in the nucleus of quite a few tumor or non tumor derived mammalian cell lines. (screeninglibraries.com)

q11) resulting in a chimeric bcr-abl (e1a2 breakpoint) fusion gene that encodes a 190 KD protein (p190) with constitutively active tyrosine kinase activity that can alter multiple signaling pathways, contributing to tumor growth and proliferation. (hindawi.com)
BCR-ABL oncogene encodes a BCR-ABL tyrosine kinase (TK), which triggers different downstream targets including c-Myc, STAT5 and CrkL, which participated in the control of cell differentiation, proliferation, migration and other cellular behaviors [ 3 - 5 ]. (jcancer.org)
The derivative chromosome BIBR 953 22 is the so called Philadelphia chromosome (Ph) which encodes the BCR/ABL kinase. (bios-mep.info)
The fusion gene on der9 differs between m-BCR-p185and M-BCR-p210gene encodes a small ABL/BCR with an approximate molecular mass of 40 kDa (p40transcript is detectable in 65% of the CML patients [15] and the p96transcript is present in 100% of examined patients with m-BCR Ph+ ALL [16]. (bios-mep.info)
This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. (cancerindex.org)

The BCR-ABL gene leads to the production of an abnormal protein that fuels the growth of leukemia cells. (cancercare.org)
But the abnormal BCR-ABL1 gene has instructions for an abnormal protein. (medlineplus.gov)
This new fusion gene (BCR-ABL) produces an abnormal protein that leads to the development of cancer cells. (usahealthsystem.com)
These drugs work by blocking an abnormal protein formed when parts of chromosomes 9 and 22 switch places. (dana-farber.org)
Scope includes mutations and abnormal protein expression. (cancerindex.org)

Nrf2 consists of six functional Neh domains (Neh1-Neh6), from which, the amino-terminal Neh2 domain controls binding Keap1-the inhibitor protein Kelch-like ECH-associated protein 1, that is responsible for the cytosolic sequestration of Nrf2 under physiological conditions (Fig. 2 a). (springer.com)

The Bcr-Abl point mutations, including the gatekeeper T315I mutations, are the principal cause for the development of resistance to TKIs. (eurekaselect.com)

Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. (hindawi.com)
Due to bcr-abl fusion, the corresponding p190 joint region contains an amino acid sequence unique to the oncoprotein in addition to a novel amino acid, not belonging to either BCR or ABL sequences, created at the exact fusion point. (hindawi.com)

Taken as a pill once or twice daily, TKIs target the protein made by the mutated BCR-ABL fusion gene. (cancercare.org)
Ponatinib is often used to treat CML that has a specific additional alteration in the BCR-ABL gene known as T315I, which makes CML cells resistant to treatment with other TKIs. (cancercare.org)

Through the fusion to BCR, ABL constitutively activates its down-stream signaling pathways, including RAS, JAK/STAT and PI-3 kinase [1,12]. (bios-mep.info)

In models of Ph+ ALL we show that the functional interplay between ABL/BCR and BCR/ABL not only increases the transformation potential of BCR/ABL but is also indispensable for the growth and survival of Ph+ ALL leukemic cells. (bios-mep.info)
Such CTL recognize HLA-matched, BCR-ABL-positive leukemic cells, implying efficient natural processing and presentation of these junctional peptides. (pasteur.fr)
The bcr-abl oncoprotein has uncontrolled tyrosine kinase activity, which deregulates cellular proliferation, decreases adherence of leukemia cells to the bone marrow stroma, and protects leukemic cells from normal programmed cell death (apoptosis). (msdmanuals.com)

We found that JOA at lower concentration significantly inhibited the proliferation of CML cells expressing mutant BCR-ABL (T315I mutation included) and wild-type BCR-ABL, which was due to that JOA induced the cell differentiation and the cell cycle arrest at G0/G1 phase. (jcancer.org)
Mechanistically, the cell differentiation mediated by JOA may be originated from the inhibition of BCR-ABL/c-MYC signaling in CML cells expressing wild-type BCR-ABL and BCR-ABL-T315I. (jcancer.org)

The abnormal BCR-ABL1 gene is formed when pieces of chromosomes 9 and 22 break off and trade places. (medlineplus.gov)

In CML, a balanced (9;22) chromosomal translocation results in a chimeric BCR-ABL fusion gene. (medscape.com)

We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. (lu.se)
In fact M-BCR p210is associated with primarily myeloid leukemia. (bios-mep.info)
c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. (jefferson.edu)

Furthermore, TRAIL expression was reduced in leukemia cells carrying the t(8;21) translocation, where the RUNX1-ETO chimeric protein interfere with normal RUNX1 function. (bvsalud.org)

Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. (jefferson.edu)

Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. (lu.se)
Our previous study has shown that CCAAT-enhancer binding protein β (C/EBPβ) is an important regulator in METH-induced neuronal autophagy and apoptosis. (cancerindex.org)
Most importantly, S-20-induced autophagy activates the ERK pathway and then inhibits the expression of drug resistance protein, which is the main reason to overcome K562/ADR resistance, rather than apoptosis. (bvsalud.org)

The fusion proteins p185and p210are mutant ABL kinases. (bios-mep.info)
Receptor Tyrosine Kinases (RTKs) are a family of tyrosine protein kinases. (callaix.com)

Binding mode and structural elements of Bcr-Abl inhibition are discussed with emphasis on pathways involved in this complex disease to determine alternative strategies and combination therapies. (eurekaselect.com)

What is a BCR-ABL1 genetic test? (medlineplus.gov)
A BCR-ABL1 genetic test uses a sample of blood or bone marrow to look for an abnormal gene called BCR-ABL1 . (medlineplus.gov)
There are different types of BCR-ABL1 genetic tests. (medlineplus.gov)
An abnormal BCR-ABL1 gene is an acquired genetic change. (medlineplus.gov)
Why do I need a BCR-ABL1 genetic test? (medlineplus.gov)
If your health care provider thinks you may have a type of leukemia that involves the BCR-ABL1 gene , you may need a BCR-ABL1 genetic test to make a diagnosis. (medlineplus.gov)
A recombinant fusion protein is a protein created through genetic engineering of a fusion gene. (chemeurope.com)

Native BCR acts as a negative regulator of proliferation and oncogenic transformation by a down-regulation of RAS-mediated signaling [18]. (bios-mep.info)
This gene codes a fusion protein with high tyrosine kinase activity, resulting in growth factor-independent proliferation. (medscape.com)
The PI3K/Akt/mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. (go.jp)

The mutant proteins often retain some of their capabilities but are no longer sensitive to the controls that regulate the normal form of the protein. (cancerquest.org)

Some medicines target the protein made by the BCR-ABL1 gene. (medlineplus.gov)

A calbindin protein that is differentially expressed in distinct populations of NEURONS throughout the vertebrate and invertebrate NERVOUS SYSTEM, and modulates intrinsic neuronal excitability and influences LONG-TERM POTENTIATION. (lookformedical.com)

Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation. (jefferson.edu)

Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. (eurekaselect.com)

IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically. (lu.se)

The p96and p40are BCR mutants [17]. (bios-mep.info)

Discontinuation of therapy is attractive to both patients and physicians because maintaining a stable BCR-ABL transcript level without therapy would imply true operational CML cure. (mcmaster.ca)

What pathways are this gene/protein implicaed in? (cancerindex.org)

Recent studies utilizing immunohistochemistry evaluation of ordinary and tumor tissue unveiled that Kaiso protein is predominantly localized inside the cytoplasm in the cell or is totally absent, though. (screeninglibraries.com)

It has been suggested that Recombinant fusion proteins, Chimera (protein) be merged into this article or section. (chemeurope.com)
Recombinant fusion proteins are be created artificially by recombinant DNA technology for use in biological research or therapeutics. (chemeurope.com)
Electrophoresis mobility shift assay of the RUNX1 consensus sequence of the TRAIL promoter with recombinant RUNX1 and CBFß proteins was also performed. (bvsalud.org)
Exogenous treatment of recombinant TRAIL proteins was found to induce leukemia cell death. (bvsalud.org)

They can act as transport proteins, regulator proteins, or activator proteins. (lookformedical.com)

If the two entities are proteins, often linker (or "spacer") peptides are also added which make it more likely that the proteins fold independently and behave as expected. (chemeurope.com)

Several drugs made from chimeric proteins are currently available for medical use. (chemeurope.com)

The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. (bios-mep.info)

Several chimeric protein dugss are TNFα blockers, such as Etanercept , Infliximab , and Adalimumab . (chemeurope.com)

1 probable explanation is the fact that Kaiso, like other proteins or variables that normally reside during the cytoplasm, need a post translational modification, to get targeted and translocated towards the cell nucleus. (screeninglibraries.com)

Omar Alkharabsheh, M.D., a medical oncologist and hematologist at the USA Health Mitchell Cancer Institute, said the standard treatment for CML is an oral therapy that specifically targets the activity of the BCR-ABL fusion protein. (usahealthsystem.com)

We present a method enabling simultaneous, ultra-high throughput single-cell barcoding of millions of cells for targeted analysis of proteins and RNAs. (nature.com)
The protein causes certain bone marrow cells to make large numbers of abnormal white blood cells. (medlineplus.gov)
Today, patients generally have the option to stop TKI treatment if they have been taking the drug for three years and have had no evidence of the DNA for BCR-ABL for two years -- that is, an ultra-sensitive PCR test detects no cancer cells in their blood. (dana-farber.org)
We also measured the levels of phosphorylated tuberous sclerosis complex 2 (TSC2) protein and Parkin protein level in SH-SY5Y cells. (cancerindex.org)
Proteins are constantly being phosphorylated and dephosphorylated in living cells. (callaix.com)
For instance, how can cells control the diverse patterns of glycosylation of various secretory proteins in the endoplasmic reticulum and Golgi in an orderly manner with high accuracy? (go.jp)

To overcome these difficulties, scientists are working on an approach that would target another protein - the so-called JAK2 kinase. (rxwiki.com)

This product is a MHC pentamer of peptide composed BCR-ABL 210 kD fusion protein-derived peptide of ATGFKQSSK sequence covering 259-269 and A*03:01, A*11:01 molecule. (peptides.de)
The junctional region of the BCR-ABLb3a2 molecule represents a potential leukemia-specific antigen which could be recognized by cytotoxic T lymphocytes (CTL). (pasteur.fr)
[6] SNPs may be synonymous with no change in amino acid or nonsynonymous resulting in amino acid substitution causing alteration in the protein molecule. (brjnmims.org)

BCR harbors both RHO-GEF and RAC-GAP functions and controls cytoskeleton modeling by regulating the activity of RHO-like GTPases [17,20]. (bios-mep.info)

The drug selectively inhibits the kinase activity of the BCR ABL fusion protein. (screeninglibraries.com)

Protein enzymes are chains of amino acids and when a phosphoryl group, PO32−, is covalently attached to one of the amino acids, it changes the three-dimensional configuration and function of the protein. (callaix.com)
Like tyrosine, serine and threonine are amino acid building blocks for protein. (callaix.com)

Hence, BCR-ABL oncogene has been the target for the treatment of patients with CML. (jcancer.org)

CML is triggered by a chromosomal abnormality (an error during cell growth) in which the ABL gene is mistakenly joined to the BCR gene, forming a mutated BCR-ABL "fusion gene. (cancercare.org)
That DNA sequence will then be expressed by a cell as a single protein. (chemeurope.com)
The presence of ABL/BCR changed the phenotype of the leukemia most likely due to its capacity CR2 to influence the stem cell population as shown by our data. (bios-mep.info)
The inhibitory effect of BCR/ABL on the B-cell signaling is counteracted by the ABL/BCRs, the reciprocal t(9;22) fusion proteins [13]. (bios-mep.info)

Also detection of fusion proteins using immunobead assays was introduced. (wikipedia.org)

Anatomy30

Organisms15

Diseases20

Chemicals and Drugs99

Analytical, Diagnostic and Therapeutic Techniques and Equipment29

Phenomena and Processes69

Technology, Industry, Agriculture2

Information Science3

Chromosome 226

GENES14

Proto-Oncogene3

Imatinib11

CHRONIC9

P2101

MRNA5

Inhibitors5

Encodes5

Abnormal protein5

Inhibitor1

Mutations1

P1902

TKIs2

Constitutively1

Leukemic cells3

T315I2

Chromosomes 9 and 221

CHROMOSOMAL TRANSLOCATION1

Myeloid3

Translocation1

Breakpoint1

Apoptosis3

Kinases2

Inhibition1

Genetic7

Proliferation3

Mutant1

Target the protein made1

Differentially1

Oncogenic1

Transformation1

Intracellular1

Mutants1

Transcript1

Pathways1

Tumor1

Recombinant4

Regulator1

Peptides1

Drugs1

Selective1

Chimeric protein1

Cytoplasm1

Targets1

Cells6

JAK21

Molecule3

Cytoskeleton1

Inhibits1

Amino2

Patients1

Cell4

Detection1